12:00 AM
Apr 04, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Erbitux cetuximab regulatory update

Merck submitted an application to EMA to extend the indication for Erbitux cetuximab to include first-line treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) with high EGFR-expression in combination with platinum-based...

Read the full 152 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >